In a previous newsletter we discussed the new biologic drug Dupixent (Dupilumab) as a true “Godsend” for severe eczema.\u00a0 By way of reminder, it is a monoclonal antibody that blocks the interleukin-4 receptor, and thereby prevents the inflammation that causes eczema.\u00a0 This medicine has proven to be both safe and effective, and the injections can be done at home.<\/p>\n
Because interleukin-4 also plays a big role in asthmatic inflammation, researchers at Washington University have studied its benefits in severe steroid-dependent asthmatics.\u00a0 Their study showed it to be both safe and effective for this disease also.<\/p>\n
Dupixent use saw a 70% decrease in need for systemic steroids, and 59% fewer asthmatic attacks.<\/p>\n
If other scientists confirm these finding it might allow the FDA to approve Dupixent for asthma therapy.\u00a0 At present the monoclonal antibodies for severe asthma (Xolair, Fasenra, Cinqair and Nucala) work very well, but must be administered in a doctor’s office.\u00a0 Dupixent may offer an at-home alternative.<\/p>\n","protected":false},"excerpt":{"rendered":"
In a previous newsletter we discussed the new biologic drug Dupixent (Dupilumab) as a true “Godsend” for severe eczema.\u00a0 By way of reminder, it is a monoclonal antibody that blocks the interleukin-4 receptor, and thereby prevents the inflammation that causes eczema.\u00a0 This medicine has proven to be both safe and effective, and the injections can be done at home. Because interleukin-4 also plays a big role in asthmatic inflammation, researchers at Washington University have studied its benefits in severe steroid-dependent…<\/p>\n